|
private:livingcelltechnologies
|
554992
|
May 29th, 2019 12:00AM
|
Living Cell Technologies Limited
|
703
|
20.00
|
Open
|
Biotechnology
|
May 29th, 2019 01:12PM
|
May 29th, 2019 01:12PM
|
LCT is a cell-based biotechnology developing insulin producing porcine pancreatic islets for the treatment of type 1 diabetes . LCT's lead product, DIABECELL is in Phase II clinical trial. LCT's encapsulation technology immunoisolates cells and allows cell implants without the use of immunosuppressive drugs.
LCT has a pipeline of of neurotrophin producing cells for Parkinson's disease, Huntington's disease, stroke and Hearing Loss.
LCT owns a unique source of high health status pigs suitable as a source of tissue for human therapeutics.
LCT invites collaboration and strategic partnerships for the further development of cell therapeutics, cell encapsulation and the use of porcine tissue as a source of biomaterials.
|
Open
|
Cell-based biotechnology
|
Open
|
PO Box 23566
|
Auckland
|
|
NZ
|
2155
|
|
Living Cell Technologies
|
|
Health Care Equipment & Services
|
|
private:livingcelltechnologies
|
554992
|
Feb 17th, 2018 12:00AM
|
Living Cell Technologies Limited
|
624
|
20.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
LCT is a cell-based biotechnology developing insulin producing porcine pancreatic islets for the treatment of type 1 diabetes . LCT's lead product, DIABECELL is in Phase II clinical trial. LCT's encapsulation technology immunoisolates cells and allows cell implants without the use of immunosuppressive drugs.
LCT has a pipeline of of neurotrophin producing cells for Parkinson's disease, Huntington's disease, stroke and Hearing Loss.
LCT owns a unique source of high health status pigs suitable as a source of tissue for human therapeutics.
LCT invites collaboration and strategic partnerships for the further development of cell therapeutics, cell encapsulation and the use of porcine tissue as a source of biomaterials.
|
|
|
|
|
|
|
|
|
|
Living Cell Technologies
|
|
Health Care Equipment & Services
|
|
private:livingcelltechnologies
|
554992
|
Feb 16th, 2018 12:00AM
|
Living Cell Technologies Limited
|
624
|
20.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
LCT is a cell-based biotechnology developing insulin producing porcine pancreatic islets for the treatment of type 1 diabetes . LCT's lead product, DIABECELL is in Phase II clinical trial. LCT's encapsulation technology immunoisolates cells and allows cell implants without the use of immunosuppressive drugs.
LCT has a pipeline of of neurotrophin producing cells for Parkinson's disease, Huntington's disease, stroke and Hearing Loss.
LCT owns a unique source of high health status pigs suitable as a source of tissue for human therapeutics.
LCT invites collaboration and strategic partnerships for the further development of cell therapeutics, cell encapsulation and the use of porcine tissue as a source of biomaterials.
|
|
|
|
|
|
|
|
|
|
Living Cell Technologies
|
|
Health Care Equipment & Services
|
|
private:livingcelltechnologies
|
554992
|
Feb 15th, 2018 12:00AM
|
Living Cell Technologies Limited
|
624
|
20.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
LCT is a cell-based biotechnology developing insulin producing porcine pancreatic islets for the treatment of type 1 diabetes . LCT's lead product, DIABECELL is in Phase II clinical trial. LCT's encapsulation technology immunoisolates cells and allows cell implants without the use of immunosuppressive drugs.
LCT has a pipeline of of neurotrophin producing cells for Parkinson's disease, Huntington's disease, stroke and Hearing Loss.
LCT owns a unique source of high health status pigs suitable as a source of tissue for human therapeutics.
LCT invites collaboration and strategic partnerships for the further development of cell therapeutics, cell encapsulation and the use of porcine tissue as a source of biomaterials.
|
|
|
|
|
|
|
|
|
|
Living Cell Technologies
|
|
Health Care Equipment & Services
|
|
private:livingcelltechnologies
|
554992
|
Feb 14th, 2018 12:00AM
|
Living Cell Technologies Limited
|
624
|
20.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
LCT is a cell-based biotechnology developing insulin producing porcine pancreatic islets for the treatment of type 1 diabetes . LCT's lead product, DIABECELL is in Phase II clinical trial. LCT's encapsulation technology immunoisolates cells and allows cell implants without the use of immunosuppressive drugs.
LCT has a pipeline of of neurotrophin producing cells for Parkinson's disease, Huntington's disease, stroke and Hearing Loss.
LCT owns a unique source of high health status pigs suitable as a source of tissue for human therapeutics.
LCT invites collaboration and strategic partnerships for the further development of cell therapeutics, cell encapsulation and the use of porcine tissue as a source of biomaterials.
|
|
|
|
|
|
|
|
|
|
Living Cell Technologies
|
|
Health Care Equipment & Services
|
|
private:livingcelltechnologies
|
554992
|
Feb 13th, 2018 12:00AM
|
Living Cell Technologies Limited
|
624
|
20.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
LCT is a cell-based biotechnology developing insulin producing porcine pancreatic islets for the treatment of type 1 diabetes . LCT's lead product, DIABECELL is in Phase II clinical trial. LCT's encapsulation technology immunoisolates cells and allows cell implants without the use of immunosuppressive drugs.
LCT has a pipeline of of neurotrophin producing cells for Parkinson's disease, Huntington's disease, stroke and Hearing Loss.
LCT owns a unique source of high health status pigs suitable as a source of tissue for human therapeutics.
LCT invites collaboration and strategic partnerships for the further development of cell therapeutics, cell encapsulation and the use of porcine tissue as a source of biomaterials.
|
|
|
|
|
|
|
|
|
|
Living Cell Technologies
|
|
Health Care Equipment & Services
|
|
private:livingcelltechnologies
|
554992
|
Feb 12th, 2018 12:00AM
|
Living Cell Technologies Limited
|
624
|
20.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
LCT is a cell-based biotechnology developing insulin producing porcine pancreatic islets for the treatment of type 1 diabetes . LCT's lead product, DIABECELL is in Phase II clinical trial. LCT's encapsulation technology immunoisolates cells and allows cell implants without the use of immunosuppressive drugs.
LCT has a pipeline of of neurotrophin producing cells for Parkinson's disease, Huntington's disease, stroke and Hearing Loss.
LCT owns a unique source of high health status pigs suitable as a source of tissue for human therapeutics.
LCT invites collaboration and strategic partnerships for the further development of cell therapeutics, cell encapsulation and the use of porcine tissue as a source of biomaterials.
|
|
|
|
|
|
|
|
|
|
Living Cell Technologies
|
|
Health Care Equipment & Services
|
|
private:livingcelltechnologies
|
554992
|
Feb 11th, 2018 12:00AM
|
Living Cell Technologies Limited
|
624
|
20.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
LCT is a cell-based biotechnology developing insulin producing porcine pancreatic islets for the treatment of type 1 diabetes . LCT's lead product, DIABECELL is in Phase II clinical trial. LCT's encapsulation technology immunoisolates cells and allows cell implants without the use of immunosuppressive drugs.
LCT has a pipeline of of neurotrophin producing cells for Parkinson's disease, Huntington's disease, stroke and Hearing Loss.
LCT owns a unique source of high health status pigs suitable as a source of tissue for human therapeutics.
LCT invites collaboration and strategic partnerships for the further development of cell therapeutics, cell encapsulation and the use of porcine tissue as a source of biomaterials.
|
|
|
|
|
|
|
|
|
|
Living Cell Technologies
|
|
Health Care Equipment & Services
|
|
private:livingcelltechnologies
|
554992
|
Feb 10th, 2018 12:00AM
|
Living Cell Technologies Limited
|
624
|
20.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
LCT is a cell-based biotechnology developing insulin producing porcine pancreatic islets for the treatment of type 1 diabetes . LCT's lead product, DIABECELL is in Phase II clinical trial. LCT's encapsulation technology immunoisolates cells and allows cell implants without the use of immunosuppressive drugs.
LCT has a pipeline of of neurotrophin producing cells for Parkinson's disease, Huntington's disease, stroke and Hearing Loss.
LCT owns a unique source of high health status pigs suitable as a source of tissue for human therapeutics.
LCT invites collaboration and strategic partnerships for the further development of cell therapeutics, cell encapsulation and the use of porcine tissue as a source of biomaterials.
|
|
|
|
|
|
|
|
|
|
Living Cell Technologies
|
|
Health Care Equipment & Services
|
|
private:livingcelltechnologies
|
554992
|
Feb 9th, 2018 12:00AM
|
Living Cell Technologies Limited
|
624
|
20.00
|
Open
|
Biotechnology
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
LCT is a cell-based biotechnology developing insulin producing porcine pancreatic islets for the treatment of type 1 diabetes . LCT's lead product, DIABECELL is in Phase II clinical trial. LCT's encapsulation technology immunoisolates cells and allows cell implants without the use of immunosuppressive drugs.
LCT has a pipeline of of neurotrophin producing cells for Parkinson's disease, Huntington's disease, stroke and Hearing Loss.
LCT owns a unique source of high health status pigs suitable as a source of tissue for human therapeutics.
LCT invites collaboration and strategic partnerships for the further development of cell therapeutics, cell encapsulation and the use of porcine tissue as a source of biomaterials.
|
|
|
|
|
|
|
|
|
|
Living Cell Technologies
|
|
Health Care Equipment & Services
|